Document is current
Any future updates will be listed below
-
Authors
Mease, Philip J. https://orcid.org/0000-0002-6620-0457
Papademetriou, Eros https://orcid.org/0000-0002-9932-566X
Potluri, Ravi https://orcid.org/0000-0002-0509-2659
Agarwal, Ekta
Cappelleri, Joseph C. https://orcid.org/0000-0001-9586-0748
Ling, You-Li
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 15 May 2024
First Online: 14 August 2024
Declarations
:
: Philip J Mease has received consultant fees from AbbVie, Acelyrin, Aclaris, Alumis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, MoonLake, Novartis, Pfizer Inc, Sun Pharma, Takeda, UCB, and Ventyx; research support from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Sun Pharma, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. Eros Papademetriou and Ravi Potluri are employees of Putnam Associates, which was a paid contractor and consultant to Pfizer in connection with the analysis. Ekta Agarwal, Joseph C Cappelleri, and You-Li Ling are employees and shareholders of Pfizer Inc.
: The data were statistically de-identified, compliant with the Health Insurance Portability and Accountability Act of 1996, and the research was deemed exempt from institutional review board approval. Access to the Optum® Clinformatics® Data Mart and the Merative™ MarketScan® databases was allowed under license for this study.
